Lipanthyl Supra

Fenofibrate, the active ingredient in Lipanthyl Supra, is a fibrate presented as an oral tablet for systemic use. It is indicated for the management of elevated triglyceride levels and mixed dyslipidaemia in adult patients, often as part of a broader lipid‑lowering regimen.

GNH USA supplies Lipanthyl Supra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets through established distribution networks and responsive customer support.

Fenofibrate is used to treat disorders of lipid metabolism, particularly elevated triglycerides and mixed dyslipidaemia.

- Hypertriglyceridaemia: reduces plasma triglyceride concentrations, helping to lower the risk of pancreatitis. - Mixed dyslipidaemia: lowers triglycerides and modestly raises HDL‑cholesterol, improving overall lipid profile. - Primary hypercholesterolaemia (adjunct therapy): contributes to additional triglyceride reduction when used with statins.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia may occur. - Headache: mild to moderate intensity reported by some patients. - Elevated liver enzymes: transient increases in ALT or AST can be observed.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy: muscle pain with weakness and elevated CK levels. - Severe liver injury: jaundice, hepatitis or hepatic failure in rare cases. - Acute pancreatitis: sudden abdominal pain with elevated pancreatic enzymes. - Allergic reactions: rash, pruritus or anaphylaxis. - Renal dysfunction: acute kidney injury reported in isolated instances.

Before initiating therapy, clinicians should evaluate relevant patient factors and monitor during treatment. - Renal function: assess baseline creatinine and monitor periodically. - Hepatic function: avoid use in active liver disease and check liver enzymes regularly. - Drug interactions: review concomitant medications, especially statins and anticoagulants. - Pregnancy and lactation: prescribe only if potential benefit outweighs risk. - Cardiovascular disease: monitor lipid levels and clinical response. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Fenofibrate may interact with several medicines; careful assessment is required.

Major Interactions (Avoid): - Statins (especially high‑dose gemfibrozil): increased risk of myopathy. - Cyclosporine: elevated fenofibrate plasma concentrations. - Anticoagulants (warfarin): potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Bile acid sequestrants: may reduce fenofibrate absorption. - Thiazide diuretics: can raise serum uric acid levels. - Oral contraceptives: may alter lipid response and require monitoring.